News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genetic Immunity Develops Unique Nanomedicine Formulation for DermaVir Therapeutic Vaccine for HIV/AIDS


5/13/2010 9:03:57 AM

MCLEAN, Va. & BUDAPEST, Hungary--(BUSINESS WIRE)--Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company’s innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES